Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 118 participants.

Also called NCT03207945

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 118 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03207945
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03207945. Randomized; quadruple masking; primary purpose treatment. Start 2018-04-30 (actual); primary completion 2025-08-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
Acronym
EPIC-HIV
Condition
Dyslipidemias
Condition
Cardiovascular Diseases
Condition
HIV Infections
Intervention (Drug)
Alirocumab
Intervention (Other)
Placebo
Lead sponsor
University of California, San Francisco (class: other)
Collaborator
Massachusetts General Hospital (class: other)

Record details

Record id
cardio:ct-nct03207945
Content hash
eba239ad34dcffe310eca4fe125c8fcdd1dce6887c334def79ac74a41710eff6